

## Introduction

- In Canada, drugs are approved for use by the regulatory body of Health Canada
- Health Technology Assessments (HTA) are conducted by the Canadian Agency for Drugs and Technologies in Health (CADTH), and they provide recommendations on whether the drug should be funded publicly
- Following HTA reviews by CADTH, a drug product file is sent to the pan-Canadian Pharmaceutical Alliance (pCPA) for negotiations of confidential rebates.
- The decision to publicly fund or “list” drugs in Canada remains to respective public drug plans (federal, provincial, and territorial).
- Individual public drug plan decisions can lead to unequal access across the country.

## Objective

- The objective of this analysis was to evaluate listing status across the public drug plans for the latest innovative dermatology products available on the Canadian market

## Methods

- Dermatology products that received a CADTH recommendation between January 1, 2016 to December 31, 2021 were collected.
- Products with no CADTH recommendation but had that reached a pCPA agreement for a dermatology were also collected.
- The outcome and date of the CADTH recommendation, pCPA letter of intent (LOI), and listing status on the public drug plans were recorded.
- Listing status was updated as of September 30, 2022
- A status of “Listed” was recorded regardless of type of listing (ex. Full benefit vs. limited use)
- An analysis of percentage listing across the drug plans was calculated using all products and products that had a signed pCPA LOI.
- The following public drug plans were used for this analysis: BC, Alberta, Saskatchewan, Manitoba, Ontario, NB, NS, PEI, NL, and NIHB

## Results

### Results – Dermatology Products

- Eleven (11) innovative dermatology products were identified between Jan 1, 2016 and Dec 31, 2021. Ten with a positive CADTH recommendation and 1 without a CADTH recommendation but with a signed pCPA LOI (Table 1).
- Indications included plaque psoriasis, atopic dermatitis, and actinic keratosis.
- As of September 30, 2022, eight of the eleven products had a signed pCPA LOI; no agreement was reached with three of the products for the dermatology indication.

Table 1. Innovative dermatology products indication and key Canadian market access dates

Product	Indication	NOC Date	CADTH Recommendation Date	pCPA LOI Date
Ilumya	Moderate to-severe plaque psoriasis.	May 19, 2021	June 21, 2021	December 20, 2021
Dupixent	Moderate to severe atopic dermatitis.	November 30, 2017	April 22, 2020	February 25, 2021
Cimzia	Moderate to severe plaque psoriasis.	November 13, 2019	November 20, 2019	No agreement
Skyrizi	Moderate to severe plaque psoriasis.	April 17, 2019	May 28, 2019	November 28, 2019
Siliq	Moderate to severe plaque psoriasis.	March 6, 2018	June 20, 2018	December 14, 2018
Tremfya	Moderate to severe plaque psoriasis.	November 10, 2017	February 21, 2018	No agreement
Actikerall	Slightly palpable and/or moderately thick hyperkeratotic actinic keratosis.	July 31, 2014	March 22, 2017	August 22, 2018
Otezla	Moderate to severe plaque psoriasis.	November 12, 2014	October 26, 2016	No agreement
Taltz	Moderate to severe plaque psoriasis.	May 25, 2016	October 25, 2016	December 29, 2017
Duobrii	Moderate to severe plaque psoriasis.	June 10, 2020	October 28, 2020	November 30, 2021
Enstilar	Psoriasis vulgaris.	September 13, 2016	N/A	August 27, 2018

Abbreviations: CADTH =Canadian Agency for Drugs and Technologies in Health; LOI = letter of intent; NOC = notice of compliance; pCPA = pan-Canadian Pharmaceutical Alliance

## Conclusion

- Seven out of 10 drug plans have 100% coverage of the products with a pCPA LOI.
- AB and PEI list 88% (7/8) and 75% (6/8) of products respectively.
- However, BC only lists 25% (2/8) of the products with a pCPA LOI.
- There is unequal and inequitable access of innovative dermatology products for patients in BC compared to the rest of Canada.
- There are further inequalities for First Nations communities in BC when compared to First Nations in the rest of the country. First Nations communities in Canada (except BC) are covered by NIHB where they have access to all innovative dermatology products.

### Results – Drug Listing

- All three products that did not have a signed pCPA LOI have no listings on the public drug plan formularies (Figure 1, Figure 2)
- Of the products that have a signed pCPA LOI (N=8), percent listing across the drug plans ranged from 25%-100%. Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Newfoundland and Labrador, and NIHB have 100% coverage of the eight products.
- In British Columbia (BC) there was only 25% (2/8) of the products listed, the next lowest is Prince Edward Island at 75% (6/8).

Figure 1. Heat map of public drug plan listing for innovative dermatology products.





Figure 2. Percentage listing by drug plan for all dermatology products and products that have a pCPA LOI.



Abbreviations: AB = Alberta; BC = British Columbia; LOI = letter of intent; MB = Manitoba; NIHB = non-insured health benefits; ON = Ontario; NB = New Brunswick; NL = Newfoundland and Labrador; NS = Nova Scotia; pCPA = pan-Canadian Pharmaceutical Alliance; SK = Saskatchewan